BioSpace News Archive

Company has patent pending for cannabinoids in the treatment of diseases through its A3 adenosine receptor (A3AR) technology platform

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it has partnered with ProPharma Group, the leading provider of regulatory and compliance services to the pharmaceutical, biotech, and medical device industries. As part of the agre

- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced that it has received written notification from The Nasdaq Stock Market (“Nasdaq”) dated December 11, 2020 that it has granted the company’s request for a 180-day exte

- Potential to be the first vaccine for the prevention of coxsackievirus B, a presumed infectious trigger in the development of type 1 diabetes and celiac disease -

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced listing another U.S. patent in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”) for AMZEEQ ® (minocycline) topical foam, 4%, for the topical treatment of inflammatory lesions o

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has received a formal notice of allowance from the U.S. Patent and Trademark Office (USPTO) for the Company’s patent application covering its pharmaceutical isotretinoin

Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it will host a key opinion leader (KOL) webinar discussing the use of the GENFLEX™ Molecular System for COVID-19 testing and the role of testing in a post-vaccine treatment environment, on Thursday, December 17, 2020 at 12:00pm Eastern Time. Infectious disease specialists Bruce Hanna, PhD, NYU Grossman Sch

Sensus Healthcare, Inc. announces that it has entered into a new exclusive distribution agreement with Ekpac Healthcare Ltd. to market Sensus SRT-100™ systems in China and Hong Kong.

The rising number of pet owners across the world has driven the demand from a widespread network of industries catering to various demands of pet animals.

Telemedicine, the future of healthcare services, refers to offering assistance to patients from a distance. Chronic care management services, a part of the umbrella term of telemedicine, are redefining the scope of this market.